HCA Healthcare, Inc. (HCA) Stock Analysis
Recovery setup
Healthcare · Medical Care Facilities
Hold if already holding. Not a fresh buy at $396.93, but acceptable to hold if already in. Reason: Weak growth.
HCA Healthcare operated 190 hospitals and 152 freestanding outpatient facilities across 19 states and England at December 31, 2025. The company generated $75.6 billion in revenues in 2025, with 49% from managed care and private insurers, 33% from Medicare programs, and 13% from... Read more
Hold if already holding. Not a fresh buy at $396.93, but acceptable to hold if already in. Reason: Weak growth. Chart setup: Death cross but MACD improving, RSI 53. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About HCA Healthcare, Inc.
About HCA Healthcare, Inc.
HCA Healthcare generated $75.6 billion in revenues for the year ended December 31, 2025, operating 190 hospitals — 179 general acute care, seven behavioral, and four rehabilitation — plus 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers across 19 states and England. Managed care and private insurers accounted for 48.9% of revenues, with Medicare and Managed Medicare combined contributing 32.7% and Medicaid programs 12.7%. The company is incorporated in Delaware and headquartered in Nashville, Tennessee.
HCA earns revenue through inpatient and outpatient services reimbursed under Medicare and Medicaid prospective payment systems, negotiated managed care contracts, and direct patient payments. For federal fiscal year 2026, CMS increased inpatient MS-DRG payment rates by approximately 2.6%, reflecting a 3.3% market basket update reduced by a 0.7 percentage point productivity adjustment; outpatient PPS rates increased by the same margin. Facilities are heavily concentrated in Florida and Texas, exposing the company to state-specific regulatory, economic, and weather conditions. Labor represents a significant cost factor: the company competes for nurses, physicians, and other clinical staff in tight markets, faces mandatory staffing-ratio requirements in certain states, and may incur higher contract labor costs during shortages. HCA's total indebtedness stood at $46.5 billion at December 31, 2025, subject to covenants in its senior unsecured credit facility and note indentures.
Show full overview
HCA's payer mix exposes the company to federal reimbursement policy changes. CMS outpatient rates face an additional 0.5% annual reduction for approximately 16 years beginning in 2026, an offset from the U.S. Supreme Court's June 2022 ruling that invalidated CMS's 340B payment reduction policy — a recovery mechanism that could weigh on outpatient revenue margins over the period. Separately, the Hospital Readmission Reduction Program can reduce inpatient payments by up to 3% for facilities with excess 30-day readmission rates across six designated conditions, including heart attack and pneumonia, adding performance-contingent risk on top of base rate dynamics.
See also: Healthcare · Medical Care Facilities
From HCA Healthcare, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-17Recent Developments — HCA Healthcare, Inc.
Latest news
- NEWS Robert W. Baird Has Lowered Expectations for HCA Healthcare (NYSE:HCA) Stock Price - MarketBeat — MarketBeat negative
- NEWS Cantor Fitzgerald reiterates HCA Healthcare stock rating at Overweight - Investing.com — Investing.com positive
- NEWS HCA Healthcare Inc. stock outperforms competitors despite losses on the day - MarketWatch — MarketWatch positive
- NEWS How To Earn $500 A Month From HCA Healthcare Stock Ahead Of Q1 Earnings - Benzinga — Benzinga positive
- NEWS Universal Beteiligungs und Servicegesellschaft mbH Sells 11,258 Shares of HCA Healthcare, Inc. $HCA - MarketBeat — MarketBeat neutral
Generated 2026-06-17T09:12:24Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicFlorida and Texas10-K Item 1: 'Our facilities are heavily concentrated in Florida and Texas, which makes us sensitive to regulatory, economic, public health, environmental and competitive conditions'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $396.93, but acceptable to hold if already in. Reason: Weak growth. Chart setup: Death cross but MACD improving, RSI 53. Maintain position. Not compelling to add more. Target $453.21 (+14.2%), stop $375.41 (−5.7%), A.R:R 1.4:1. Score 5.8/10, moderate confidence.
Take-profit target: $453.21 (+14.2% upside). Target $453.21 (+14.2%), stop $375.41 (−5.7%), A.R:R 1.4:1. Stop-loss: $375.41.
Weak growth.
HCA Healthcare, Inc. trades at a P/E of 13.4 (forward 11.8). TrendMatrix value score: 7.5/10. Verdict: Hold.
30 analysts cover HCA with a consensus score of 3.8/5. Average price target: $504.
What does HCA Healthcare, Inc. do?HCA Healthcare operated 190 hospitals and 152 freestanding outpatient facilities across 19 states and England at...
HCA Healthcare operated 190 hospitals and 152 freestanding outpatient facilities across 19 states and England at December 31, 2025. The company generated $75.6 billion in revenues in 2025, with 49% from managed care and private insurers, 33% from Medicare programs, and 13% from Medicaid programs. Facilities are heavily concentrated in Florida and Texas.